Exhibit 99.1
Millipore Reports Third Quarter Financial Results
Strong Revenue Growth Drives Third Quarter Performance
BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 1, 2006--Millipore
Corporation (NYSE:MIL), a leading provider of products and services
that improve productivity in the laboratory and in biopharmaceutical
manufacturing, today reported financial results for its third quarter
ended September 30, 2006.
Revenues for the third quarter grew 38 percent totaling $330.1
million. Changes in foreign exchange rates during the quarter
increased total revenue growth by 2 percent. Millipore completed its
acquisition of Serologicals during the third quarter. Excluding the
impact of Serologicals and currency rate changes, Millipore's total
revenue growth in the third quarter was 10 percent, which included 13
percent growth in its Bioprocess Division and 6 percent growth in its
Bioscience Division.
The Company reported third quarter net income of $14.8 million, or
$0.27 per share, compared to net income of $22.9 million or $0.44 per
share in the third quarter of 2005. Non-GAAP net income grew
approximately 20 percent in the third quarter totaling $37.1 million,
or $0.69 per share, compared to non-GAAP net income of $31.1 million,
or $0.59 per share in the third quarter of 2005. A reconciliation of
all GAAP to non-GAAP financial measures is provided in the Company's
financial tables accompanying this press release.
For the first nine months of 2006, Millipore reported total
revenues of $872.3 million. Excluding the impact of Serologicals and
currency rate changes, total revenue growth was 11 percent, compared
to the Company's full-year 2006 guidance of 10 to 12 percent. The
Company reported nine month net income of $78.5 million, or $1.45 per
share, compared to net income of $79.2 million, or $1.55 per share in
2005. Non-GAAP net income for the first three quarters of 2006 was
$115.8 million, or $2.14 per share, compared to $100.6 million, or
$1.97 per share in 2005.
"The initiatives we are implementing to accelerate our performance
are working and we are on track to generate a second straight year of
attractive organic revenue growth, while increasing our non-GAAP
profitability," said Martin Madaus, Chairman & CEO of Millipore. "We
are executing well and building a strong pipeline of opportunities in
both divisions. Our Bioscience Division generated a strong quarter in
North America for our laboratory water and sample preparation
products, while our Bioprocess Division continues to benefit from
healthy demand for our filtration and chromatography products.
"Since the beginning of 2005, we have broadened our product
portfolio and significantly improved our performance. We are
participating in many new and attractive market segments, and our
long-term growth prospects are stronger today than they were in the
past. Over the next three quarters, we will be focused on completing
the integration of Serologicals and fully capturing the value of this
transaction. We are applying many of the same strategies and
initiatives to the integration that we have applied to improve our own
performance over the past seven quarters. Despite a slow start in
certain segments of Serologicals' business, our success in driving
operational improvements and cost synergies will enable us to meet our
guidance of $3.00 to $3.10 in non-GAAP earnings per share for 2006."
Third Quarter Highlights
-- Strong quarter in North America for laboratory water and
sample preparation & biotools business units
-- Bioprocess growth benefited from strong demand for virus
filtration and chromatography media
-- Completed acquisition of Serologicals on July 14, 2006; third
quarter results reflect 11 weeks of Serologicals financial
performance
-- Opened new $50 million R&D Center for Bioprocess Division
-- Successfully reached mid-point of five year Global Supply
Chain Initiative; project on track to deliver $40 million of
annual savings by 2009 and will cost $10 million less than
original forecast
Revenue Growth by Geography ($ millions):
Three Months Ended Nine Months Ended
----------------------- -----------------------
Sept. Sept.
30, Oct. 1, % 30, Oct. 1, %
2006 2005 Growth 2006 2005 Growth
------- ------- ------- ------- ------- -------
Americas $151.5 $103.1 47% $381.5 $309.9 23%
Europe 126.8 95.3 33% 347.3 296.2 17%
Asia/Pacific 51.8 41.2 26% 143.5 128.6 12%
------- ------- ------- -------
Total $330.1 $239.6 38% $872.3 $734.7 19%
======= ======= ======= =======
Revenue Growth by Division ($ millions):
Three Months Ended Nine Months Ended
----------------------- -----------------------
Sept. Sept.
30, Oct. 1, % 30, Oct. 1, %
2006 2005 Growth 2006 2005 Growth
------- ------- ------- ------- ------- -------
Bioprocess $194.9 $145.7 34% $525.5 $443.8 18%
Bioscience 135.2 93.9 44% 346.8 290.9 19%
------- ------- ------- -------
Total $330.1 $239.6 38% $872.3 $734.7 19%
======= ======= ======= =======
Quarterly Earnings Call
Millipore will host a conference call and webcast to discuss its
financial results, business outlook, and related corporate and
financial matters at 4:45 p.m. Eastern Time today. The call can be
accessed through Millipore's Web site: http://www.millipore.com. A
replay of the call will be archived on the Investor Relations section
of the website and will also be available via telephone by dialing
(800) 642-1687 or (706) 645-9291 and entering confirmation code:
8952877. The telephonic replay will be available beginning at 8:00
p.m. ET on November 1, 2006 until 8:00 p.m. ET on November 3, 2006.
About Millipore
Millipore is a leading provider of products and services that
improve productivity in biopharmaceutical manufacturing and in
clinical, analytical and research laboratories. The Company is
organized in two operating divisions. Its Bioprocess Division helps to
enable pharmaceutical and biotechnology companies to optimize their
manufacturing productivity, ensure the quality of drugs, and scale up
the production of difficult-to-manufacture biologics. Its Bioscience
Division helps to optimize laboratory productivity and workflows by
providing reagents, kits and other enabling technologies and products
for life science research and development. Millipore has a deep
understanding of its customers' research and manufacturing process
needs, and offers reliable and innovative tools, technologies and
services. The Company is part of the S&P 500 Index and employs
approximately 5,800 employees worldwide. For additional information on
Millipore Corporation, please visit its website at: www.millipore.com.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release - which
are non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP
operating margin, non-GAAP pre-tax income, non-GAAP net income, and
non-GAAP diluted earnings per share - exclude stock based compensation
expense, costs related to our manufacturing consolidation strategy,
severance related to leadership changes and division consolidation,
acquisition and financing expenses related to the acquisition of
Serologicals, amortization of intangible assets and inventory fair
value adjustments related to business acquisitions, and accrual for
environmental site remediation costs. There are limitations in using
non-GAAP financial measures as they are not prepared in accordance
with generally accepted accounting principles and may be different
than non-GAAP financial measures used by other companies.
We believe that the non-GAAP financial measures provide useful and
supplementary information to investors regarding our quarterly
performance. It is our belief that these non-GAAP financial measures
have been particularly useful to investors over the last couple of
years because of the significant changes that have occurred outside of
our day-to-day business in accordance with the execution of our new
strategy. This strategy includes strengthening our leadership position
with bioscience customers, becoming a strategic supplier in bioscience
research markets, leading our industry in product quality and
manufacturing effectiveness, becoming a magnet for talent, and
doubling the value of the Company by 2009. The financial impact of
certain elements of these activities, particularly leadership changes,
our manufacturing consolidation strategy, division consolidation, and
acquisitions, are often large relative to our overall financial
performance and most of the related charges are recorded in one or two
financial quarters but not in other financial quarters, which can
adversely affect the comparability of our results on a
period-to-period comparable basis. In addition, certain activities,
such as the significant costs associated with consolidating
manufacturing facilities, business acquisitions, and environmental
site remediation costs, happen infrequently and the underlying costs
associated with such activities impact a limited number of quarters
significantly, but do not recur. As an example, the scope and scale of
our manufacturing consolidation strategy was the largest in our
history. When we complete this initiative, we will have closed eight
manufacturing plants. Beginning in the first quarter of 2006, we
excluded, and will continue to exclude during 2006, stock based
compensation expense from our non-GAAP results.
We regularly use non-GAAP financial measures internally to
understand, manage, and evaluate our business results and make
operating decisions. We also measure our employees and compensate
them, in part, based on such non-GAAP measures. For the same reasons,
we also use this information for our forecasting activities. The
non-GAAP financial measures presented herein also facilitate
comparisons to our historical operating results, which have
consistently been presented in this manner.
Non-GAAP financial measures should not be considered as a
substitute for, or superior to, measures of financial performance
prepared in accordance with GAAP. They are limited in value because
they exclude charges that have a material effect on our reported
results and, therefore, should not be relied upon as the sole
financial measures to evaluate our financial results. The non-GAAP
financial measures are meant to supplement, and to be viewed in
conjunction with, GAAP financial measures. Investors are encouraged to
review the reconciliation of the financial measures to their most
directly comparable GAAP financial measures as provided in the tables
accompanying this press release. Our earnings guidance, however, is
only provided on a non-GAAP basis. It is not feasible to provide GAAP
diluted earnings per share guidance because the items excluded, other
than amortization expense, are difficult to predict and estimate and
are primarily dependent on future events.
Forward Looking Statements:
The matters discussed herein, as well as in future oral and
written statements by management of Millipore Corporation that are
forward-looking statements, are based on current management
expectations that involve substantial risks and uncertainties which
could cause actual results to differ materially from the results
expressed in, or implied by, these forward-looking statements.
Potential risks and uncertainties that could affect Millipore's
future operating results include, without limitation, the inability to
successfully integrate Serologicals or other acquired businesses,
failure to achieve design wins into our pharmaceutical and
biotechnology customers' manufacturing design phase for a particular
drug; delay, suspension or termination of a customer's volume
production; lack of availability of raw materials or component
products on a timely basis; regulatory delay in the approval of new
therapeutics; limitations on cash flow for operations and investment
due to increased debt service obligations; the inability to establish
and maintain necessary product and process quality levels; reduced
demand for cell culture products using bovine serum; the inability to
realize the expected benefits of development, marketing, licensing and
other alliances; competitive factors such as new membrane or
chromatography technology; the inability to achieve anticipated cost
benefits of our supply chain initiative; risks relating to our
concentration of principal manufacturing operations; the inability to
utilize technology in current or planned products due to overriding
rights by third parties; potential environmental liabilities;
conditions in the economy in general and in the bioscience and
bioprocess markets in particular; foreign exchange fluctuations;
reduced private and government research funding; exposure to product
liability claims; and difficulties inherent in transferring or
outsourcing of manufacturing operations. Please refer to our filings
with the SEC, including our most recent Annual Report on Form 10-K,
for more information on these and other risks that could cause actual
results to differ.
Millipore Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
Three Months Ended Nine Months Ended
------------------- -------------------
September October September October
30, 1, 30, 1,
2006 2005 2006 2005
--------- --------- --------- ---------
Net sales $330,117 $239,557 $872,307 $734,699
Cost of sales 169,261 116,862 425,282 347,090
--------- --------- --------- ---------
Gross profit 160,856 122,695 447,025 387,609
Selling, general and
administrative expenses 106,785 72,601 276,609 230,584
Research and development
expenses 24,637 18,858 62,767 52,272
--------- --------- --------- ---------
Operating income 29,434 31,236 107,649 104,753
Interest income 4,713 894 20,873 2,202
Interest expense (16,548) (1,432) (28,733) (5,021)
--------- --------- --------- ---------
Income before income taxes and
minority interest 17,599 30,698 99,789 101,934
Provision for income taxes 2,347 7,824 20,348 22,783
Minority interest 439 - 960 -
--------- --------- --------- ---------
Net income $14,813 $22,874 $78,481 $79,151
========= ========= ========= =========
Diluted earnings per share $0.27 $0.44 $1.45 $1.55
========= ========= ========= =========
Diluted weighted average shares
outstanding 54,172 52,579 54,168 51,185
========= ========= ========= =========
Millipore Corporation
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
September December
30, 31,
2006 2005
----------- -----------
ASSETS
Current assets:
Cash and cash equivalents $91,408 $537,052
Marketable securities - 113,839
Accounts receivable, net 252,198 188,130
Inventories 278,425 153,030
Assets held for sale 19,090 -
Deferred income taxes and other current assets 91,854 75,050
----------- -----------
Total current assets 732,975 1,067,101
Property, plant and equipment, net 500,473 371,249
Deferred income taxes 83,810 73,190
Intangible assets, net 496,913 43,421
Goodwill 1,055,103 82,718
Other assets 25,476 8,986
----------- -----------
Total assets $2,894,750 $1,646,665
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Notes Payable $100,000 $-
Accounts payable 91,598 79,587
Accrued expenses and other current liabilities 161,482 115,655
Income taxes payable and deferred income taxes 46,240 47,357
----------- -----------
Total current liabilities 399,320 242,599
Long-term debt 1,342,393 552,285
Deferred income taxes 164,972 5,713
Other liabilities 53,591 54,505
Minority interest 4,136 -
Shareholders' equity 930,338 791,563
----------- -----------
Total liabilities and shareholders' equity $2,894,750 $1,646,665
=========== ===========
Millipore Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Three Months Ended September 30, 2006
(dollars in thousands, except EPS data)
Gross Gross Operating Operating
Profit Profit Income Margin
Margin
-------------------------------------
GAAP results, three months ended
September 30, 2006 $160,856 48.7% $29,434 8.9%
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 4,474 1.4% 4,474 1.4%
Acquisition inventory fair
value amortization 13,279 4.0% 13,279 4.0%
Stock-based compensation
expense 474 0.1% 3,246 1.0%
Acquisition integration and
restructuring expenses 399 0.1% 6,105 1.9%
Purchased intangibles
amortization 2,153 0.7% 6,065 1.8%
Environmental accrual 2,100 0.6%
--------- ------- --------- ---------
Total non-GAAP adjustments 20,779 6.3% 35,269 10.7%
--------- ------- --------- ---------
Non-GAAP results, three months
ended September 30, 2006 $181,635 55.0% $64,703 19.6%
========= ======= ========= =========
Pre-tax Net Diluted
Income Income EPS
--------------------------
GAAP results, three months ended September
30, 2006 $17,599 $14,813 $0.27
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 4,474 2,811 0.06
Acquisition inventory fair value
amortization 13,279 8,344 0.16
Stock-based compensation expense 3,246 2,211 0.04
Acquisition integration and restructuring
expenses 6,105 3,836 0.07
Purchased intangibles amortization 6,065 3,811 0.07
Environmental accrual 2,100 1,319 0.02
-------- -------- -------
Total non-GAAP adjustments 35,269 22,332 0.42
-------- -------- -------
Non-GAAP results, three months ended
September 30, 2006 $52,868 $37,145 $0.69
======== ======== =======
(a) Please refer to our press release for a full explanation for the
use of non-GAAP measures.
Millipore Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Nine Months Ended September 30, 2006
(dollars in thousands, except EPS data)
Gross Gross Operating Operating
Profit Profit Income Margin
Margin
-------------------------------------
GAAP results, nine months ended
September 30, 2006 $447,025 51.2% $107,649 12.3%
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 15,038 1.7% 15,038 1.8%
Acquisition inventory fair
value amortization 13,279 1.5% 13,279 1.6%
Stock-based compensation
expense 1,320 0.2% 8,960 1.0%
Acquisition integration and
restructuring expenses 469 0.1% 8,060 0.9%
Purchased intangibles
amortization 2,153 0.2% 8,985 1.0%
Environmental accrual 2,100 0.2%
Bridge loan commitment fees in
connection with acquisition of
Serologicals
--------- ------- --------- ---------
Total non-GAAP adjustments 32,259 3.7% 56,422 6.5%
--------- ------- --------- ---------
Non-GAAP results, nine months
ended September 30, 2006 $479,284 54.9% $164,071 18.8%
========= ======= ========= =========
Pre-tax Net Diluted
Income Income EPS
----------------------------
GAAP results, nine months ended September
30, 2006 $99,789 $78,481 $1.45
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 15,038 9,778 0.18
Acquisition inventory fair value
amortization 13,279 8,344 0.15
Stock-based compensation expense 8,960 6,128 0.11
Acquisition integration and
restructuring expenses 8,060 5,171 0.09
Purchased intangibles amortization 8,985 5,722 0.11
Environmental accrual 2,100 1,319 0.03
Bridge loan commitment fees in
connection with acquisition of
Serologicals 1,310 895 0.02
--------- --------- -------
Total non-GAAP adjustments 57,732 37,357 0.69
--------- --------- -------
Non-GAAP results, nine months ended
September 30, 2006 $157,521 $115,838 $2.14
========= ========= =======
(a) Please refer to our press release for a full explanation for the
use of non-GAAP measures.
Millipore Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Three Months Ended October 1, 2005
(dollars in thousands, except EPS data)
Gross Gross Operating Operating
Profit Profit Income Margin
Margin
-------------------------------------
GAAP results, three months ended
October 1, 2005 $122,695 51.2% $31,236 13.0%
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 4,435 1.9% 4,435 1.9%
Acquisition inventory fair
value amortization 1,907 0.8% 1,907 0.8%
Costs related to divisional
consolidation 3,148 1.3%
Purchased intangibles
amortization 1,261 0.5%
--------- ------- --------- ---------
Total non-GAAP adjustments 6,342 2.7% 10,751 4.5%
--------- ------- --------- ---------
Non-GAAP results, three months
ended October 1, 2005 $129,037 53.9% $41,987 17.5%
========= ======= ========= =========
Pre-tax Net Diluted
Income Income EPS
--------------------------
GAAP results, three months ended October 1,
2005 $30,698 $22,874 $0.44
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 4,435 3,382 0.06
Acquisition inventory fair value
amortization 1,907 1,454 0.03
Costs related to divisional consolidation 3,148 2,400 0.04
Purchased intangibles amortization 1,261 962 0.02
-------- -------- -------
Total non-GAAP adjustments 10,751 8,198 0.15
-------- -------- -------
Non-GAAP results, three months ended October
1, 2005 $41,449 $31,072 $0.59
======== ======== =======
(a) Please refer to our press release for a full explanation for the
use of non-GAAP measures.
Millipore Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Nine Months Ended October 1, 2005
(dollars in thousands, except EPS data)
Gross Gross Operating Operating
Profit Profit Income Margin
Margin
-------------------------------------
GAAP results, nine months ended
October 1, 2005 $387,609 52.8% $104,753 14.3%
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 7,011 0.9% 7,011 1.0%
Acquisition inventory fair
value amortization 1,907 0.3% 1,907 0.2%
Costs related to divisional
consolidation 3,195 0.4%
Executive termination costs 12,050 1.7%
Purchased intangibles
amortization 2,767 0.4%
In-process R&D write-off 3,149 0.4%
--------- ------- --------- ---------
Total non-GAAP adjustments 8,918 1.2% 30,079 4.1%
--------- ------- --------- ---------
Non-GAAP results, nine months
ended October 1, 2005 $396,527 54.0% $134,832 18.4%
========= ======= ========= =========
Pre-tax Net Diluted
Income Income EPS
----------------------------
GAAP results, nine months ended October 1,
2005 $101,934 $79,151 $1.55
Non-GAAP adjustments:
Costs related to manufacturing
consolidation strategy 7,011 4,993 0.10
Acquisition inventory fair value
amortization 1,907 1,358 0.03
Costs related to divisional
consolidation 3,195 2,276 0.04
Executive termination costs 12,050 8,582 0.17
Purchased intangibles amortization 2,767 1,971 0.04
In-process R&D write-off 3,149 2,243 0.04
--------- --------- -------
Total non-GAAP adjustments 30,079 21,423 0.42
--------- --------- -------
Non-GAAP results, nine months ended
October 1, 2005 $132,013 $100,574 $1.97
========= ========= =======
(a) Please refer to our press release for a full explanation for the
use of non-GAAP measures.
Non-GAAP Gross Profit and Gross Profit Margin
The calculation of non-GAAP gross profit and gross profit margin
is displayed in the above tables. Non-GAAP gross profit and gross
profit margin exclude the costs related to our manufacturing
consolidation strategy for the reasons described above in the
introductory paragraphs of the "Use of Non-GAAP Financial Measures"
section of this press release. Non-GAAP gross margin and gross profit
margin exclude the amortization of acquired inventory fair value
adjustments from business acquisitions because (1) the amounts are
non-cash, (2) we can not influence the timing and amount of future
expense recognition, and (3) excluding such expenses provides
investors and management better visibility into the components of
operating expenses. Non-GAAP gross profit and gross profit margin also
exclude stock-based compensation expense because the accounting
treatment on a year-over-year basis for option grants has changed with
the adoption of Statement of Financial Accounting Standards ("SFAS")
No. 123 (revised 2004), Share-based Payment ("SFAS 123R"). We
implemented the new accounting standard using the modified prospective
method, which does not allow for restatement of prior period results
and, accordingly, renders the year-over-year comparison not
meaningful. In addition, non-GAAP gross profit and gross profit margin
exclude the one-time acquisition and related integration expenses in
connection with the acquisition of Serologicals.
Non-GAAP Operating Income and Operating Margin
The calculation of non-GAAP operating income and operating margin
is displayed in the above tables. Non-GAAP operating income and
operating margin exclude the amortization of intangible assets and
acquired inventory fair value adjustments related to business
acquisitions because (1) the amounts are non-cash, (2) we can not
influence the timing and amount of future expense recognition, and (3)
excluding such expenses provides investors and management better
visibility into the components of operating expenses. The calculation
of Non-GAAP operating income and operating margin also exclude the
costs related to our manufacturing consolidation strategy and
severance related to leadership changes and division consolidation for
the reasons described above in the introductory paragraphs of the "Use
of Non-GAAP Financial Measures" section of this press release.
Non-GAAP operating income and operating margin exclude stock-based
compensation expense because the accounting treatment on a
year-over-year basis for option grants has changed with the adoption
of SFAS No. 123R. We implemented the new accounting standard using the
modified prospective method, which does not allow for restatement of
prior period results and, accordingly, renders the year-over-year
comparison not meaningful. Non-GAAP operating income and operating
margin exclude one-time acquisition and related integration expenses
in connection with the acquisition of Serologicals because this is the
largest acquisition in recent Millipore history. In addition, we have
also excluded environmental site remediation costs from the non-GAAP
operating income and operating margin because these costs are
significant and non-recurring for Millipore.
Non-GAAP Pre-tax Income
The calculation of non-GAAP pre-tax income is displayed in the
above tables. Non-GAAP pre-tax income excludes bridge loan commitment
fees in connection with the acquisition of Serologicals. The
calculation of non-GAAP pre-tax income also excludes costs related to
our manufacturing consolidation strategy; severance related to
leadership changes and division consolidation; stock-based
compensation expense; acquisition and integration expenses;
amortization of intangible assets and acquired inventory fair value
adjustments related to business acquisitions; and environmental site
remediation costs for the reasons described for operating income and
operating margin above.
Non-GAAP Net Income
The calculation of non-GAAP net income is displayed in the above
tables. Because pre-tax income is included in the net income
calculation, the net income calculation excludes costs related to our
manufacturing consolidation strategy; severance related to leadership
changes and division consolidation; stock-based compensation expense;
acquisition and integration expenses and bridge loan commitment fees
in connection with the acquisition of Serologicals; amortization of
intangible assets and acquired inventory fair value adjustments
related to business acquisitions; and environmental site remediation
costs for the reasons described for pre-tax income above.
Non-GAAP Diluted Earnings per Share
The calculation of non-GAAP diluted earnings per share is
displayed in the above tables. Because net income is included in the
diluted earnings per share calculation, the diluted earnings per share
calculation excludes the amounts for costs related to our
manufacturing consolidation strategy; severance related to leadership
changes and division consolidation; stock-based compensation expense;
acquisition expenses and bridge loan commitment fees in connection
with the acquisition of Serologicals; amortization of intangible
assets and acquired inventory fair value adjustments related to
business acquisitions; and environmental site remediation costs for
the reasons described for net income above.
CONTACT: Joshua Young
Director, Investor Relations
(978) 715 - 1527
(800) 225 - 3384
joshua_young@millipore.com
OR
Lynn Garvin
Vice President, Corporate Communications
Millipore Corporation
978-715-1043
lynn_garvin@millipore.com
